Cholecalciferol

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1999

www.ebi.ac.uk

First approval year: 1999
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Cholecalciferol
www.ebi.ac.uk

Molecular weight: 384.65
www.ebi.ac.uk

Structure (SMILES): C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12
www.ebi.ac.uk

accrete d3
Accrete d3
aciferol d3
Aciferol d3
adcal d3
Adcal-d3
biolife vitamin d3
Biolife vitamin d3
cacit d3
Cacit d3
calceos
Calceos
calci d
Calci-d
calcichew d3
Calcichew d3
calcichew d3 fte
Calcichew d3 fte
calcichew d3 once daily
Calcichew d3 once daily
cholecalciferol component of dp r206 vitamin d3
Cholecalciferol component of dp-r206 vitamin d3
cholecalciferol component of fosamax plus d
Cholecalciferol component of fosamax plus d
colecal d3

And 75 more, listed on the interactive page.

1000 ne kolekalciferol vitamin d3
2400 IU Vitamin D3 (cholecalciferol)
2400 iu vitamin d3 cholecalciferol
400 IU Vitamin D3 (cholecalciferol)
6400 IU Vitamin D3 (cholecalciferol)
7 dehydrocholesterol activated
7-dehydrocholesterol, activated
Active Comparator: Vigantol Oil (Vitamin D3)
Adcal-D3
aquadetrim
Aquadetrim
arachitol
Arachitol
Calcichew D3
calciol
Calciol
calcirol
Calcirol
capsudar d3 100e
CapsuDar D3 100E
cholecalciferol
Cholecalciferol
CHOLECALCIFEROL
Cholecalciferol (2000iu qd)
Cholecalciferol (inactive vitamin D)

And 159 more, listed on the interactive page.

ATC classification codes

A11CC05

Sources for recorded values

www.ebi.ac.uk

CAS registry numbers

67-97-0

ChEMBL ID: CHEMBL1042
www.ebi.ac.uk

InChIKey: QYSXJUFSXHHAJI-YRZJJWOYSA-N
www.ebi.ac.uk

PubChem compound IDs

5280795

RxNorm IDs (RxCUI)

2418

FDA ingredient codes (UNII)

1C6V77QF41

Applicant: SANDOZ CANADA INC
Approval date: 21 Feb 2001
Application number: NDA021265

First in class: No
Orphan designation: No
Availability: Prescription only

Pharmacology name: vitamin D3
Type: Metabolite
Drug name stem: -calci-

Administration routes

Oral
Parenteral

Mechanisms of action

Mechanism
Vitamin D receptor agonist
Action type
Agonist
Target
Vitamin D3 receptor
Protein identifier
P11473

Open Targets mechanisms

Mechanism
Vitamin D receptor agonist
Action type
Agonist
Target
Vitamin D3 receptor

DrugCentral mechanisms

Action type
Agonist
Gene symbol
VDR
Protein identifier
P11473
Organism
Homo sapiens
Target development level
Clinical

Condition
Leukemia, Lymphocytic, Chronic, B-Cell
Highest recorded phase
3
Condition identifier
EFO:0000095
Subject identifier
D015451
Condition
HIV Infections
Highest recorded phase
3
Condition identifier
EFO:0000180
Subject identifier
D015658
Condition
Metabolic Syndrome
Highest recorded phase
2
Condition identifier
EFO:0000195
Subject identifier
D024821
Condition
Leukemia, Myeloid, Acute
Highest recorded phase
2
Condition identifier
EFO:0000222
Subject identifier
D015470
Condition
Dermatitis, Atopic
Highest recorded phase
2
Condition identifier
EFO:0000274
Subject identifier
D003876
Condition
Barrett Esophagus
Highest recorded phase
0.5
Condition identifier
EFO:0000280
Subject identifier
D001471
Condition
Breast Neoplasms
Highest recorded phase
3
Condition identifier
EFO:0000305
Subject identifier
D001943
Condition
Cardiovascular Diseases
Highest recorded phase
3
Condition identifier
EFO:0000319
Subject identifier
D002318
Condition
Pulmonary Disease, Chronic Obstructive
Highest recorded phase
2
Condition identifier
EFO:0000341
Subject identifier
D029424
Condition
Colorectal Neoplasms
Highest recorded phase
3
Condition identifier
EFO:0000365
Subject identifier
D015179
Condition
Crohn Disease
Highest recorded phase
3
Condition identifier
EFO:0000384
Subject identifier
D003424
Condition
Diabetes Mellitus
Highest recorded phase
2
Condition identifier
EFO:0000400
Subject identifier
D003920
Condition
Lymphoma, Large B-Cell, Diffuse
Highest recorded phase
3
Condition identifier
EFO:0000403
Subject identifier
D016403
Condition
Carcinoma, Intraductal, Noninfiltrating
Highest recorded phase
1
Condition identifier
EFO:0000432
Subject identifier
D002285
Condition
Epilepsy
Highest recorded phase
3
Condition identifier
EFO:0000474
Subject identifier
D004827
Condition
Glioblastoma
Highest recorded phase
1
Condition identifier
EFO:0000519
Subject identifier
D005909
Condition
Infections
Highest recorded phase
3
Condition identifier
EFO:0000544
Subject identifier
D007239
Condition
Irritable Bowel Syndrome
Highest recorded phase
1
Condition identifier
EFO:0000555
Subject identifier
D043183
Condition
Polycystic Ovary Syndrome
Highest recorded phase
3
Condition identifier
EFO:0000660
Subject identifier
D011085
Condition
Prostatic Neoplasms
Highest recorded phase
3
Condition identifier
EFO:0000673
Subject identifier
D011471
Condition
Psoriasis
Highest recorded phase
2
Condition identifier
EFO:0000676
Subject identifier
D011565
Condition
Severe Acute Respiratory Syndrome
Highest recorded phase
3
Condition identifier
EFO:0000694
Subject identifier
D045169
Condition
Skin Diseases
Highest recorded phase
1
Condition identifier
EFO:0000701
Subject identifier
D012871
Condition
Colitis, Ulcerative
Highest recorded phase
3
Condition identifier
EFO:0000729
Subject identifier
D003093
Condition
Melanoma
Highest recorded phase
3
Condition identifier
EFO:0000756
Subject identifier
D008545

And 77 more, listed on the interactive page.

Condition identifier
EFO_0000095
Highest recorded phase
3
Condition identifier
EFO_0000195
Highest recorded phase
2
Condition identifier
EFO_0000274
Highest recorded phase
2
Condition identifier
EFO_0000341
Highest recorded phase
2
Condition identifier
EFO_0000384
Highest recorded phase
3
Condition identifier
EFO_0000389
Condition identifier
EFO_0000400
Highest recorded phase
3
Condition identifier
EFO_0000403
Highest recorded phase
3
Condition identifier
EFO_0000474
Highest recorded phase
3
Condition identifier
EFO_0000495
Highest recorded phase
1
Condition identifier
EFO_0000519
Condition identifier
EFO_0000544
Highest recorded phase
3
Condition identifier
EFO_0000660
Highest recorded phase
3
Condition identifier
EFO_0000694
Condition identifier
EFO_0000701
Condition identifier
EFO_0000729
Highest recorded phase
3
Condition identifier
EFO_0000756
Highest recorded phase
3
Condition identifier
EFO_0000764
Highest recorded phase
2
Condition identifier
EFO_0001073
Highest recorded phase
3
Condition identifier
EFO_0002496
Highest recorded phase
2
Condition identifier
EFO_0002503
Highest recorded phase
3
Condition identifier
EFO_0002546
Condition identifier
EFO_0002950
Highest recorded phase
3
Condition identifier
EFO_0003047
Highest recorded phase
3
Condition identifier
EFO_0003095
Highest recorded phase
3

And 204 more, listed on the interactive page.

Event
abdominal discomfort
Reports
2,565
Reporting signal score
6,885.98
Event
alopecia
Reports
2,627
Reporting signal score
7,084.39
Event
anaemia postoperative
Reports
114
Reporting signal score
380.812
Event
anti-cyclic citrullinated peptide antibody positive
Reports
990
Reporting signal score
4,668.33
Event
arthralgia
Reports
1,345
Reporting signal score
1,341.82
Event
arthritis
Reports
284
Reporting signal score
318.599
Event
arthropathy
Reports
1,579
Reporting signal score
4,532.05
Event
asthma
Reports
382
Reporting signal score
434.206
Event
blister
Reports
492
Reporting signal score
900.087
Event
blood cholesterol increased
Reports
365
Reporting signal score
666.653
Event
bone disorder
Reports
121
Reporting signal score
163.795
Event
bursitis
Reports
162
Reporting signal score
359.63
Event
calciphylaxis
Reports
65
Reporting signal score
170.594
Event
coma
Reports
196
Reporting signal score
173.044
Event
condition aggravated
Reports
1,161
Reporting signal score
1,220.22
Event
confusional state
Reports
574
Reporting signal score
506.447
Event
contusion
Reports
437
Reporting signal score
566.841
Event
dental caries
Reports
109
Reporting signal score
192.267
Event
discomfort
Reports
1,307
Reporting signal score
3,991.25
Event
drug hypersensitivity
Reports
505
Reporting signal score
183.469
Event
drug intolerance
Reports
1,521
Reporting signal score
3,160.02
Event
duodenal ulcer perforation
Reports
615
Reporting signal score
2,719.9
Event
dyspnoea
Reports
913
Reporting signal score
331.678
Event
exostosis
Reports
88
Reporting signal score
168.207
Event
fall
Reports
802
Reporting signal score
494.366

And 86 more, listed on the interactive page.

NCT00022087
clinicaltrials.gov
NCT00043069
clinicaltrials.gov
NCT00058188
clinicaltrials.gov
NCT00092066
clinicaltrials.gov
NCT00092079
clinicaltrials.gov
NCT00112437
clinicaltrials.gov
NCT00421343
clinicaltrials.gov
NCT00641771
clinicaltrials.gov
NCT00668941
clinicaltrials.gov
NCT00692913
clinicaltrials.gov
NCT00729183
clinicaltrials.gov
NCT00806416
clinicaltrials.gov
NCT00885170
clinicaltrials.gov
NCT00960934
clinicaltrials.gov
NCT00996801
clinicaltrials.gov
NCT01120600
clinicaltrials.gov
NCT01675297
clinicaltrials.gov
NCT01765010
clinicaltrials.gov
NCT01904110
clinicaltrials.gov
NCT02518763
clinicaltrials.gov
NCT03234244
clinicaltrials.gov
NCT03382314
clinicaltrials.gov
NCT03824171
clinicaltrials.gov
NCT03994172
clinicaltrials.gov
NCT00292591
clinicaltrials.gov

And 226 more, listed on the interactive page.

Dose: 1 softgel
Route: Oral
How often: Once daily

Hydrogen bond acceptors: 1
Hydrogen bond donors: 1
Polar surface area: 20.23
Calculated partition coefficient (ALogP): 7.62
Calculated partition coefficient (XLogP): 7.9
Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 1
Rotatable bonds: 6
Heavy atoms: 28
Molecular formula: C27H44O
Monoisotopic mass: 384.339216023
Natural product: Yes

0642-0093
0642-0207
0642-7473
10542-009
13925-116
13925-117
15370-103
15370-104
15370-105
15370-250
39328-106
42192-320
42192-321
42192-323
42192-332
50967-219
50967-410
52796-172
52796-173
52796-174
52796-177
58657-325
58657-326
58657-327
59088-005

And 70 more, listed on the interactive page.

Recorded assays: 1,275
Active assays: 201

Confirmatory
Other
Screening

Calcium-Regulating Hormones and Agents
id.nlm.nih.gov
Vitamins
id.nlm.nih.gov
Bone Density Conservation Agents
id.nlm.nih.gov

Related records

Trials (1,574)

'Palliative-D' Vitamin D to Palliative Cancer Patients
"HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"
"Information Technology Methodology for Patient Motivation in Diabetes Management."
"The Effect of Comprehensive Non-pharmacological Treatment on Metabolic Disorders in Type 2 Diabetic Patients"
[18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis
18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone
24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination
24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG
2D/3D Imaging to Analyze the Regeneration Rate of Autologous Bone
2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial
3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
30000 IU Per Week Vitamin D Treatment in PCOS Patients
4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients
4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control
A 28-day Clinical Study on Facial Skin Rejuvenation
A 56-day Clinical Study on Facial Skin Rejuvenation
A Clinical Intervention Study of Tangningtongluo on Diabetic Foot Ulcer

Approved for (3)

Anemia
Iron deficiency anemia
Osteoporosis

In development for (96)

Actinic keratosis Phase 2
Acute myeloid leukemia Phase 2
Adrenoleukodystrophy Phase 1
AIDS Phase 2
Allergic disease Phase 2
Asthma Phase 3
Atopic conjunctivitis Phase 2
Atopic eczema Phase 2
Autism Phase 2
B-cell chronic lymphocytic leukemia Phase 3
Barrett esophagus Early phase 1
Bone fracture Phase 3
Breast cancer Phase 3
Breast carcinoma Phase 3
Bronchiolitis Phase 2
Burn Phase 1
Cancer Phase 2
Cardiovascular disorder Phase 3
Chronic kidney disease Phase 3
Chronic obstructive pulmonary disease Phase 2

Targets (1)

VDR Vitamin D receptor agonist

Cholecalciferol

Development status

Names and chemistry

Brand names (100)

Other names (184)

Identifiers

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action

Open Targets mechanisms

DrugCentral mechanisms

Investigated indications (102)

Open Targets indications (229)

Reported adverse events (111)

Trial references (251)

Dosing

Chemical properties

National Drug Codes

Evidence counts

Active assay types (3)

Pharmacologic actions

Related records

Trials (1,574)

Approved for (3)

In development for (96)

Other linked conditions (5)

Targets (1)